Leveraging non-enzymatic functions of LSD1 for novel therapeutics

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Lysine-specific demethylase 1 (LSD1) is a crucial epigenetic regulator involved in histone demethylation.
• LSD1 possesses both enzymatic and non-enzymatic functions relevant to various diseases.
• Current clinical trials predominantly target LSD1's enzymatic activity, with limited focus on its non-enzymatic roles.

Purpose of the Study:

• To review the biological roles and structural characteristics of LSD1.
• To highlight therapeutic strategies targeting the non-enzymatic functions of LSD1.
• To discuss challenges and future directions in developing LSD1-targeting drugs.

Main Methods:

• Literature review and analysis of existing research on LSD1.
• Exploration of structural data and biological functions of LSD1.
• Discussion of therapeutic modalities including allosteric inhibitors, PPI inhibitors, and PROTACs.

Main Results:

• LSD1's non-enzymatic functions are increasingly recognized as critical in disease pathogenesis.
• A limited number of inhibitors and degraders targeting non-enzymatic functions have entered clinical assessment.
• Allosteric inhibitors, PPI inhibitors, and small-molecule degraders represent promising avenues for targeting non-enzymatic LSD1 functions.

Conclusions:

• Targeting the non-enzymatic functions of LSD1 offers a promising, yet underexplored, therapeutic avenue.
• Further research into LSD1's non-enzymatic roles and development of specific inhibitors are warranted.
• Overcoming challenges in drug discovery for non-enzymatic targets is crucial for advancing LSD1-based therapies.